Metastatic Prostate Cancer Market Report and Forecast 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Metastatic Prostate Cancer Market Overview – 8 Major Markets 
    3.1    Metastatic Prostate Cancer Market Historical Value (2017-2023) 
    3.2    Metastatic Prostate Cancer Market Forecast Value (2024-2032) 
4    Vendor Positioning Analysis
    4.1    Key Vendors
    4.2    Prospective Leaders
    4.3    Niche Leaders
    4.4    Disruptors
5    Metastatic Prostate Cancer Overview 
    5.1    Guidelines and Stages
    5.2    Pathophysiology
    5.3    Screening and Diagnosis
    5.4    Treatment Pathway 
6    Patient Profile
    6.1    Patient Profile Overview
    6.2    Patient Psychology and Emotional Impact Factors
    6.3    Risk Assessment and Treatment Success Rate
7    Metastatic Prostate Cancer Market - Epidemiology Scenario and Forecast – 8 Major Markets
    7.1    8MM Epidemiology Scenario Overview (2017-2032)
        7.1.1    Prevalence, by Country
            7.1.1.1    United States 
            7.1.1.2    United Kingdom
            7.1.1.3    EU4
            7.1.1.4    India
            7.1.1.5    Japan
        7.1.2    Diagnosed Cases, by Country
            7.1.2.1    United States 
            7.1.2.2    United Kingdom
            7.1.2.3    EU4
            7.1.2.4    India
            7.1.2.5    Japan
        7.1.3    Treatment Seeking Rate, by Country 
            7.1.3.1    United States 
            7.1.3.2    United Kingdom
            7.1.3.3    EU4
            7.1.3.4    India
            7.1.3.5    Japan
8    Metastatic Prostate Cancer Market Landscape – 8 Major Markets 
    8.1    Metastatic Prostate Cancer Market: Developers Landscape
        8.1.1    Analysis by Year of Establishment
        8.1.2    Analysis by Company Size
        8.1.3    Analysis by Region
    8.2    Metastatic Prostate Cancer Market: Product Landscape
        8.2.1    Analysis by Treatment Type
        8.2.2    Analysis by Route of Administration
9    Metastatic Prostate Cancer Market Challenges and Unmet Needs
    9.1    Treatment Pathway Challenges
    9.2    Compliance and Drop-Out Analysis
    9.3    Awareness and Prevention Gaps
10    Cost of Treatment
11    Metastatic Prostate Cancer Market Dynamics
    11.1    Market Drivers and Constraints
    11.2    SWOT Analysis
        11.2.1    Strengths
        11.2.2    Weaknesses
        11.2.3    Opportunities
        11.2.4    Threats
    11.3    PESTEL Analysis
        11.3.1    Political
        11.3.2    Economic
        11.3.3    Social
        11.3.4    Technological
        11.3.5    Legal
        11.3.6    Environment
    11.4    Porter’s Five Forces Model
        11.4.1    Bargaining Power of Suppliers
        11.4.2    Bargaining Power of Buyers
        11.4.3    Threat of New Entrants
        11.4.4    Threat of Substitutes
        11.4.5    Degree of Rivalry
    11.5    Key Demand Indicators 
    11.6    Key Price Indicators
    11.7    Industry Events, Initiatives, and Trends  
    11.8    Value Chain Analysis
12    Metastatic Prostate Cancer Market Segmentation (2017-2032) - 8 Major Markets 
    12.1    Metastatic Prostate Cancer Market (2017-2032) by Treatment Type
        12.1.1    Market Overview
        12.1.2    Chemotherapy
        12.1.3    Immunotherapy
        12.1.4    Hormonal Therapy
        12.1.5    Radiation Therapy
        12.1.6    Others
    12.2    Metastatic Prostate Cancer Market (2017-2032) by Route of Administration
        12.2.1    Market Overview  
        12.2.2    Oral
        12.2.3    Parenteral
        12.2.4    Others
    12.3    Metastatic Prostate Cancer Market (2017-2032) by End User
        12.3.1    Market Overview  
        12.3.2    Hospitals
        12.3.3    Clinics
        12.3.4    Cancer Centers
        12.3.5    Research Laboratories
        12.3.6    Others
    12.4    Metastatic Prostate Cancer Market (2017-2032) by Region
        12.4.1    Market Overview
        12.4.2    United States
        12.4.3    EU-4 and the United Kingdom
            12.4.3.1    Germany
            12.4.3.2    France
            12.4.3.3    Italy
            12.4.3.4    Spain
            12.4.3.5    United Kingdom
        12.4.4    Japan
        12.4.5    India 
13    United States Metastatic Prostate Cancer Market (2017-2032)
    13.1    United States Metastatic Prostate Cancer Market Historical Value (2017-2023) 
    13.2    United States Metastatic Prostate Cancer Market Forecast Value (2024-2032)
    13.3    United States Metastatic Prostate Cancer Market (2017-2032) by Treatment Type
        13.3.1    Market Overview
        13.3.2    Chemotherapy
        13.3.3    Immunotherapy
        13.3.4    Hormonal Therapy
        13.3.5    Radiation Therapy
        13.3.6    Others
    13.4    United States Metastatic Prostate Cancer Market (2017-2032) by Route of Administration
        13.4.1    Market Overview  
        13.4.2    Oral
        13.4.3    Parenteral
        13.4.4    Others
    13.5    United States Metastatic Prostate Cancer Market (2017-2032) by End User
        13.5.1    Market Overview  
        13.5.2    Hospitals
        13.5.3    Clinics
        13.5.4    Cancer Centers
        13.5.5    Research Laboratories
        13.5.6    Others
14    EU-4 and United Kingdom Metastatic Prostate Cancer Market (2017-2032)
    14.1    EU-4 and United Kingdom Metastatic Prostate Cancer Market Historical Value (2017-2023) 
    14.2    EU-4 and United Kingdom Metastatic Prostate Cancer Market Forecast Value (2024-2032)
    14.3    EU-4 and United Kingdom Metastatic Prostate Cancer Market (2017-2032) by Treatment Type
        14.3.1    Market Overview
        14.3.2    Chemotherapy
        14.3.3    Immunotherapy
        14.3.4    Hormonal Therapy
        14.3.5    Radiation Therapy
        14.3.6    Others
    14.4    EU-4 and United Kingdom Metastatic Prostate Cancer Market (2017-2032) by Route of Administration
        14.4.1    Market Overview  
        14.4.2    Oral
        14.4.3    Parenteral
        14.4.4    Others
    14.5    EU-4 and United Kingdom Metastatic Prostate Cancer Market (2017-2032) by End User
        14.5.1    Market Overview  
        14.5.2    Hospitals
        14.5.3    Clinics
        14.5.4    Cancer Centers
        14.5.5    Research Laboratories
        14.5.6    Others
15    Japan Metastatic Prostate Cancer Market
    15.1    Japan Metastatic Prostate Cancer Market Historical Value (2017-2023) 
    15.2    Japan Metastatic Prostate Cancer Market Forecast Value (2024-2032)
    15.3    Japan Metastatic Prostate Cancer Market (2017-2032) by Treatment Type
        15.3.1    Market Overview
        15.3.2    Chemotherapy
        15.3.3    Immunotherapy
        15.3.4    Hormonal Therapy
        15.3.5    Radiation Therapy
        15.3.6    Others
    15.4    Japan Metastatic Prostate Cancer Market (2017-2032) by Route of Administration
        15.4.1    Market Overview  
        15.4.2    Oral
        15.4.3    Parenteral
        15.4.4    Others
    15.5    Japan Metastatic Prostate Cancer Market (2017-2032) by End User
        15.5.1    Market Overview  
        15.5.2    Hospitals
        15.5.3    Clinics
        15.5.4    Cancer Centers
        15.5.5    Research Laboratories
        15.5.6    Others
16    India Metastatic Prostate Cancer Market
    16.1    India Metastatic Prostate Cancer Market Historical Value (2017-2023) 
    16.2    India Metastatic Prostate Cancer Market Forecast Value (2024-2032)
    16.3    India Metastatic Prostate Cancer Market (2017-2032) by Treatment Type
        16.3.1    Market Overview
        16.3.2    Chemotherapy
        16.3.3    Immunotherapy
        16.3.4    Hormonal Therapy
        16.3.5    Radiation Therapy
        16.3.6    Others
    16.4    India Metastatic Prostate Cancer Market (2017-2032) by Route of Administration
        16.4.1    Market Overview  
        16.4.2    Oral
        16.4.3    Parenteral
        16.4.4    Others
    16.5    India Metastatic Prostate Cancer Market (2017-2032) by End User
        16.5.1    Market Overview  
        16.5.2    Hospitals
        16.5.3    Clinics
        16.5.4    Cancer Centers
        16.5.5    Research Laboratories
        16.5.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
    17.2    US FDA
    17.3    EU EMA
    17.4    Japan PMDA
    17.5    India CDSCO
    17.6    Others
18    Patent Analysis
    18.1    Analysis by Form of Patent
    18.2    Analysis by Publication Year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation
19    Clinical Trials Analysis
    19.1    Analysis by Trial Registration Year
    19.2    Analysis by Trial Status
    19.3    Analysis by Trial Phase
    19.4    Analysis by Therapeutic Area
    19.5    Analysis by Geography
20    Grants Analysis
    20.1    Analysis by Year
    20.2    Analysis by Amount Awarded
    20.3    Analysis by Issuing Authority
    20.4    Analysis by Grant Application
    20.5    Analysis by Funding Institute
    20.6    Analysis by NIH Departments
    20.7    Analysis by Recipient Organization 
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Treatment Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Strategic Initiatives
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Treatment Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    Market Share Analysis, By Region (Top 5 Companies)
    23.2    AstraZeneca 
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Companies News and Developments
        23.2.5    Certifications 
    23.3    Pfizer, Inc.
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Companies News and Developments
        23.3.5    Certifications
    23.4      AB Science 
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Companies News and Developments
        23.4.5    Certifications
    23.5     Bristol Myers Squibb 
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Companies News and Developments
        23.5.5    Certifications
    23.6      F-Hoffmann-La Roche Ltd, 
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Companies News and Developments
        23.6.5    Certifications
    23.7    Daiichi Sankyo Inc. 
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Companies News and Developments
        23.7.5    Certifications
    23.8     Teva Pharmaceutical Industries Ltd 
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Companies News and Developments
        23.8.5    Certifications
    23.9    Sanofi 
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Companies News and Developments
        23.9.5    Certifications
    23.10     Eli Lily and Company 
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Companies News and Developments
        23.10.5    Certifications
24    Metastatic Prostate Cancer Treatment Drugs - Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Payment Methods (Additional Insight)
    26.1    Government Funded
    26.2    Private Insurance
    26.3    Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

*The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.